Effects of Acute Buprenorphine on Responses to Intranasal Cocaine: A Pilot Study

References

• Schnoll S. H., Karrigan J., Kitchen S. B., Daghestani A., Hansen T. Characteristics of cocaine abusers presenting for treatment. Cocaine Use in America: Epidemiological and Clinical Perspectives, N. J. Kozel, E. H. Adams. National Institute on Drug Abuse Research Monograph 61, U.S. Government Printing Office, Washington, D.C. 1985; 171–181
   Google Scholar
• Kosten T. R., Rounsaville B. J., Kleber H. D. A 2.5 year follow‐up of cocaine use among treated opiate addicts. Arch. Gen. Psychiatry 1987; 44: 281–284
   PubMed Web of Science ®Google Scholar
• Foltin R. W., Fischman M. W. Cardiovascular and subjective effects of intravenous cocaine and morphine combinations (“speedballs”) in humans. J. Pharmacol. Exp. Ther 1992; 261(2)623–632
   Google Scholar
• Rosen M. I., Kosten T. R. Buprenorphine: Beyond methadone. Hosp. Commun. Psychiatry 1991; 42: 347–349
   PubMedGoogle Scholar
• Johnson R. E., Jaffe J. H., Fudala P. J. A controlled trial of buprenorphine treatment for opiate dependence. JAMA 1992; 267(20)2750–2755
   PubMed Web of Science ®Google Scholar
• Walsh S. T., Preston M. D., Stitzer S. T., Dickerson S. L., Cone E. J., Bigelow G. E. The behavioral and pharmacokinetic profile of high dose buprenorphine administered sublingually in humans. Soc. Neurosci. Abstr 1991
   Google Scholar
• Lewis J. W. Buprenorphine. Drug Alcohol Depend 1985; 14: 363–372
   PubMed Web of Science ®Google Scholar
• Jasinski D. R., Hevnick J. S., Griffith J. D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry 1978; 35: 601–616
   Web of Science ®Google Scholar
• Fudala P. J., Jaffe J. H., Dax E. M. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate day administration and abrupt withdrawal. Clin. Pharmacol. Ther 1990; 47: 525–534
   PubMed Web of Science ®Google Scholar
• Brown E. E., Finlay J. M., Wong J. T., Daamsa G., Fibiger H. C. Behavioral and neurochemical interactions between cocaine and buprenorphine: Implications for the pharmacotherapy of cocaine abuse. J. Pharmacol. Exp. Ther 1991; 256: 119–126
   Google Scholar
• Kamien J. B., Spealman R. D. Modulation of the discriminative‐stimulus effects of cocaine by buprenorphine. Behav. Pharmacol 1991; 2: 517–520
   Google Scholar
• Pettit H. O., Smith S., Eckstron A. J., Pryor G. T. Evaluation of the effects of buprenorphine in both a cocaine self‐administration and drug‐discrimination paradigm. Soc. Neurosci. Abstr 1991
   Google Scholar
• Jasinski D. R., Fudala P. J., Johnson R. E. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin. Pharmacol. Ther 1989; 45: 513–519
   PubMed Web of Science ®Google Scholar
• Vining E., Kosten T. R., Kleber H. D. Clinical utility of rapid clonidine‐naltrexone detoxification for opioid abusers. Br. J. Addict 1988; 83: 567–575
   PubMedGoogle Scholar
• Van Dyke C., Jatlow P., Barash P. G., Byck R. Intranasal cocaine: Dose relationships of psychological effects and plasma levels. Int. J. Psychiatry Med 1982; 12(1)1–13
   Google Scholar
• McNair D., Lorr M., Droppleman L. F. Profile of Mood States. Educational and Industrial Testing, San Diego 1971
   Google Scholar
• Fischman M. W., Foltin R. W., Nestadt G., Pearlson G. D. Effects of desipramine maintenance on cocaine self‐administration by humans. J. Pharmacol. Exp. Ther 1990; 253: 760–770
   PubMed Web of Science ®Google Scholar
• Kosten T. A., Marby D. W., Nestler E. J. Cocaine conditioned place preference is attenuated by chronic buprenorphine treatment. Life Sci 1991a; 49: 201–207
   Google Scholar
• Suzuki T., Shiozaki Y., Masukawa Y., Misawa M., Nagasc H. The role of mu and kappa‐opioid receptors in cocaine‐induced conditioned place preference. Jpn. J. Pharmacol 1992; 58: 435–442
   PubMedGoogle Scholar
• Mello N. K., Lukas S. E., Kamien J. B., Mendelson J. H., Drieze J., Cone E. J. The effects of chronic buprenorphine treatment on cocaine and food self‐administration by rhesus monkeys. J. Pharmacol. Exp. Ther 1992; 260(3)1185–1193
   Google Scholar
• Teoh S. K., Sintavanarong P., Kuehnle J., Mendelson J. H., Hallgring E., Rhoades E., Mello N. K. Buprenorphine effects on morphine and cocaine challenges in heroin and cocaine dependent men. Proceedings of the Committee on Problems of Drug Dependence. 1991, L. S. Harris. National Institute on Drug Abuse, Rockville, Maryland, In Press
   Google Scholar
• Kosten T. R., Kleber H. D., Morgan C. Treatment of cocaine abuse with buprenorphine. Biol. Psychiatry 1989; 26: 637–639
   PubMed Web of Science ®Google Scholar
• Wilkerson P., Van Dyke C., Jatlow P., Barash P., Byck R. Intranasal and oral cocaine kinetics. Clin. Pharmacol. Ther 1980; 27(3)386–394
   Google Scholar
• Van Dyke C., Jatlow P., Barash P. G., Byck R. Oral cocaine: Plasma concentrations and central effects. Science 1978; 200(14)211–213
   Google Scholar
• Cascella N., Muntaner C., Kumor K. M., Nagoshi C. T., Jaffe J. H., Sherer M. A. Cardiovascular responses to cocaine placebo in humans: A preliminary report. Biol. Psychiatry 1989; 25: 285–295
   Google Scholar
• Kosten T. R., Schottenfeld R. S., Morgan C. H., Falcioni J., Ziedonis D. Buprenorphine vs methadone for opioid and cocaine dependence. Proceedings of the Committee on Problems of Drug Dependence. 1991, L. S. Harris. National Institute on Drug Abuse, Rockville, Maryland, In Press
   Google Scholar
• Kosten T. R., Silverman D. G., Fleming J., Kosten T. A., Gavin F. H., Compton N., Jatlow P., Byck R. Intravenous cocaine challenges during naltrexone maintenance. Biol. Psychiary
   Google Scholar